Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
about
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesThe Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-AnalysisIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized TrialsUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateMeta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidencePhase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful futureThe Influence of Biomarker Mutations and Systemic Treatment on Cerebral Metastases from NSCLC Treated with Radiosurgery.Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib.Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung CancerOverexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitorReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer.The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusHistorical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Protein kinase inhibitors to treat non-small-cell lung cancer.Pharmacotherapy targeting the EGFR oncogene in NSCLC.Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand.Experience with erlotinib in the treatment of non-small cell lung cancer.EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.A new proteomic test could guide treatment decision in second-line therapy for patients with EGFR unselected non-small cell lung cancer?Primary pulmonary adenocarcinoma in a 16-year-old boy - a five-year follow-upWhich treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy.Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.
P2860
Q26745422-192E6DCB-599B-41EA-94F4-6CE5ADD264CBQ26772052-7EC3D49E-DA23-42EC-9148-3D4464F3041FQ26798882-8345FC97-2178-4728-92F7-06F938AD85C5Q26825636-6A2C050B-5BD8-495E-AD0F-1F5E2EC7C2D8Q27022535-B4DB0C4E-EA3B-4C94-80A5-21C48E4CF1A2Q30356434-8857FC57-CAAE-4667-A45F-7DA52BB9E45DQ33416457-0B2A9BB4-E3EE-4A3A-9EBB-F45622899E18Q34011705-D48CCED1-806F-4BDF-9EF0-54D5A1B3C373Q34265813-7565289C-0629-4384-8DCC-552DB42B1CA7Q34663877-2DC27F1A-8639-4F5D-94DD-D291BFCFEE52Q35016510-7891CF4A-DF66-44AA-9ECC-FF998D0ECDD0Q35290807-A48AAA61-FA80-4E60-8A9A-BE6B22679616Q36243003-699F036C-F0A5-4BD7-8091-9621BAE18904Q36399028-F915A67C-FD90-4EE5-AFC1-AC5C7F7AC8D5Q36482556-40082377-AE36-4CDE-B902-7F8954DB0D43Q36782296-FD8DB2B8-BA46-4CB2-867B-542B928A1DA7Q37001622-ACA9DDB8-4F9C-476B-A63B-BAFA16E1FE18Q37082514-01AE72C6-D931-46F6-857D-4302D0D8B9F6Q37392573-0457024D-061B-41B5-A2B3-54F3F35D1736Q37598057-B1FC6E19-C121-487B-B841-957088D93F0EQ37637905-399F9F15-555F-4273-A417-A77825FE6FCDQ38205518-65BD8F6A-8590-4373-AC9B-5B1965A554C5Q38248997-56034806-8077-4F16-ABB4-581E862E423FQ38349157-5EDA1D99-02FA-4341-ADDC-B9C901407210Q38373208-73241FAF-194A-4DF0-97F3-016B32F05952Q38524526-0CD51D67-5202-4955-9E73-C58613DC456CQ38629823-6B61AD6E-B2AD-4D7E-848D-A0D8F90B2CF7Q38701670-3CEB3AFB-8D97-4D6B-87FD-BA0D3BA464A2Q38829545-8F53897E-0217-4667-B1E3-993C50C64159Q38936376-CA37906F-B248-4BAE-B718-415AEE586621Q38987067-42C1CE24-7DD4-4CC7-A425-948F3E80008FQ40701318-A721F5C6-C2A5-4DB7-BBDD-BAEB2FA9DF59Q41027999-54D2CDBF-FC41-425B-BA6E-B893A37BA032Q42120519-8FE47FBA-9857-4CE5-8FB6-82BAA204AEFDQ42181353-10704C46-AEC5-4F66-8582-32F9AA632E9FQ42371412-F8843D15-9098-4EE0-BD9E-E26E8E7EF16AQ42371658-5F1B099A-0C68-4DD6-9CE7-661D4A7072CEQ47861831-4AC57E63-1385-4130-A29D-B8A1720ADD9BQ47897098-30E5D67F-5050-4955-A83E-9243860C4451Q49480794-F0C92F31-865D-4D41-90F3-3B064D437EEE
P2860
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pemetrexed versus erlotinib in ...... ORG) randomized phase 3 study.
@ast
Pemetrexed versus erlotinib in ...... ORG) randomized phase 3 study.
@en
type
label
Pemetrexed versus erlotinib in ...... ORG) randomized phase 3 study.
@ast
Pemetrexed versus erlotinib in ...... ORG) randomized phase 3 study.
@en
prefLabel
Pemetrexed versus erlotinib in ...... ORG) randomized phase 3 study.
@ast
Pemetrexed versus erlotinib in ...... ORG) randomized phase 3 study.
@en
P2093
P2860
P356
P1433
P1476
Pemetrexed versus erlotinib in ...... ORG) randomized phase 3 study.
@en
P2093
Ageliki Rapti
Alexandra Voutsina
Athanasios Karampeazis
Athanasios Kotsakis
Charalambos Christofillakis
Dimitris Mavroudis
George Samonis
John Souglakos
Lambros Vamvakas
Maria Agelidou
P2860
P304
P356
10.1002/CNCR.28132
P407
P577
2013-05-09T00:00:00Z